Navigation Links
Cambridge-based Ligon Discovery Raises $1M in Seed Funding
Date:11/19/2009

CAMBRIDGE, Mass., Nov. 19 /PRNewswire/ -- Ligon Discovery, Inc., which uses proprietary small molecule microarray technology to find drugs against high-value targets, today announced that it has raised $1M in seed financing led by incTANK Ventures. The company will use the capital to complete its initial discovery campaign that will screen over 100 high-value disease protein targets. With this investment, incTANK Ventures General Partner Christian Bailey joins the board.

Patrick Kleyn PhD, Angela Koehler PhD and Benjamin Ebert MD PhD founded Ligon Discovery with an exclusive license to technology invented at Harvard University and already successfully used to find novel drug compounds at the Broad Institute.

Christian Bailey, General Partner at incTANK Ventures, commented, "Ligon represents a rare combination: although it is an early-stage company, its patented technology has already chalked up some significant drug discovery successes which big pharma companies are now pursuing."

"Ligon's technology has already been used to discover drug compounds against high value targets including protein kinases, histone deacetylases, extracellular growth factors, and transcription factors," said Patrick Kleyn, Ligon's CEO and co-founder. He added, "These compounds were subsequently validated by follow-up assays and results have been published in journals such as Nature, Nature Chemical Biology, and the Journal of the American Chemical Society."

"Ligon is a terrific example of how research at one of Massachusetts' leading academic institutions can be commercialized, leading to new jobs and new therapies that help patients," said Dr. Susan Windham-Bannister, President & CEO of the Massachusetts Life Sciences Center, the agency charged with implementing the state's ten-year, $1 billion Life Sciences Initiative. "Translating research from our world-class colleges and universities into early stage companies and life-saving products is what makes Massachusetts the hub for innovation in the life sciences."

About Ligon Discovery

Ligon Discovery is a Harvard spinout that leverages a patented platform technology to identify pre-clinical drug candidates. The company's high-throughput microarray "chip" transforms the speed of the drug discovery process and expands the scope of new drug prospecting to include previously intractable targets. The team has deployed the SMM technology, originally invented at Harvard University and further developed at the Broad Institute (founded by MIT and Harvard University) in Cambridge, and has established one of the largest small molecule screening capabilities in the industry. Using this facility, Ligon has successfully completed screens in the fields of coagulation and cancer, and is actively pursuing drug discovery in other areas of high unmet medical need. For more information, visit www.ligondiscovery.com.

About incTANK Ventures

incTANK Ventures invests in Boston area technology ventures with strong intellectual property and compelling market opportunities emerging from premier universities and research institutions. Funded innovations are often inter-disciplinary and span the applied sciences including biotechnology, life sciences, materials science, and computational science. Existing portfolio companies include Agrivida, which applies genomic technology to sugar/biofuel production, and AgaMatrix, which applies audio signal processing technologies to blood glucose monitoring. For more information, visit www.inctank.com.

About the Massachusetts Life Sciences Center

The Massachusetts Life Sciences Center (MLSC) is a quasi-public agency of the Commonwealth of Massachusetts tasked with implementing the Massachusetts Life Sciences Act, a ten-year, $1 billion initiative that was signed into law in June of 2008. The Center's mission is to create jobs in the life sciences and support vital scientific research that will improve the human condition. This work includes making financial investments in public and private institutions that are advancing life sciences research, development and commercialization as well as building ties between sectors of the Massachusetts life sciences community. For more information, visit www.masslifesciences.com.

SOURCE Ligon Discovery, Inc.


'/>"/>
SOURCE Ligon Discovery, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
2. New Company Starts, Bridging the Development Gap in the Discovery of Cancer Drugs
3. Trana Discovery and Southern Research Institute Announce the First RNA-RNA High Throughput Drug Screening Assay Platform for HIV Antivirals
4. ActiveSight and CHDI Leverage Fragment-Based Lead Discovery for Huntington Disease Therapies
5. ARCA Discovery Announces Data Demonstrating Potential for Bucindolol as Targeted Therapy in Heart Failure, Atrial Fibrillation, and Ventricular Arrhythmia
6. Five Clinical Studies to Receive $2.5 Million Under Foundations 2007 Clinical Discovery Program
7. Ambrx Enters FGF-21 Type 2 Diabetes Drug Discovery Collaboration with Merck and Co. Inc.
8. FASgen Announces New Discovery for Treatment of Stroke
9. Nobel Prize-Winning Discovery
10. Orion Genomics Announces the Discovery of Novel Breast Cancer Biomarkers
11. FASgen Announces a New Discovery in Obesity Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... The top three players dominating ... Koninklijke Philips N.V., and Schiller. Collectively, these companies held ... in 2015. Strong product portfolio and a monumental geographical ... aiding these players remain leaders in the fragmented competitive ... the global market are likely to focus on mergers ...
(Date:2/23/2017)... February 23, 2017 Tillotts Pharma ... Berlin office was opened in ... . The portfolio includes Entocort ® for the ... treatment of ulcerative colitis, and VistaPrep ® for ... Swiss specialty pharmaceutical company focused on the treatment of ...
(Date:2/23/2017)... and VANCOUVER, British Columbia , ... OGXI ) today announced its year end 2016 ... In January 2017, OncoGenex, and Achieve Life Science, Inc., ... have entered into a definitive merger agreement under which ... completion of the proposed merger, Achieve,s stockholders are expected ...
Breaking Medicine Technology:
(Date:2/23/2017)... ... February 23, 2017 , ... Rare Disease ... will be participating in Rare Disease Day events, hosted by the Rare Disease ... Disease Report, a website, weekly e-newsletter and quarterly publication, will be conducting interviews ...
(Date:2/23/2017)... ... February 23, 2017 , ... EBSCO Information ... National Institute for Health and Care Excellence (NICE) framework. The agreement ... Health Service (NHS) to search, order and purchase medical and healthcare-related content through ...
(Date:2/23/2017)... ... 23, 2017 , ... Current Meditation , a new ... throughout the U.S. starting this spring. Current Meditation focuses on “meditation for the ... Current Meditation will be the first meditation concept in the U.S. offering franchising ...
(Date:2/23/2017)... CA (PRWEB) , ... February 23, 2017 , ... Top ... Smiling Patriot program today with a new Indiegogo campaign . Individuals ... to homeless veterans in the Los Angeles area, either as a participating patient or ...
(Date:2/22/2017)... New York (PRWEB) , ... February 22, 2017 ... ... floor entrance and lobby of a new healthcare contact center in Georgia, PENETRON ... , One of the nation’s largest healthcare systems recently invested $51 million to ...
Breaking Medicine News(10 mins):